{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:33:46Z","timestamp":1761863626361},"reference-count":150,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T00:00:00Z","timestamp":1466812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.nefro.2016.05.023","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T19:15:37Z","timestamp":1473102937000},"page":"597-608","source":"Crossref","is-referenced-by-count":19,"title":["Calcificaciones cardiovasculares en la enfermedad renal cr\u00f3nica: Potenciales implicaciones terap\u00e9uticas"],"prefix":"10.1016","volume":"36","author":[{"given":"Jordi","family":"Bover","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ure\u00f1a-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"G\u00f3rriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Lloret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iara","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar","family":"Ruiz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Ballar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2016.05.023_bib0755","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2016.05.023_bib0760","doi-asserted-by":"crossref","unstructured":"Bover J, G\u00f3rriz JL, Ure\u00f1a P, Lloret MJ, DaSilva I, Ruiz-Garcia C, et al. Detecci\u00f3n de las calcificaciones cardiovasculares: \u00bfuna herramienta \u00fatil para el nefr\u00f3logo? Nefrolog\u00eda 2016 (en prensa).","DOI":"10.1016\/j.nefro.2016.05.021"},{"key":"10.1016\/j.nefro.2016.05.023_bib0765","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/kisup.2011.27","article-title":"Ten years of progress in our understanding of uremic vascular calcification and disease: A decade summarized in 20 steps","volume":"1","author":"Brandenburg","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.nefro.2016.05.023_bib0770","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ndt\/gfv021","article-title":"Con: Vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease","volume":"30","author":"Zoccali","year":"2015","journal-title":"Nephrol. Dial. Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib0775","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/ndt\/gfv019","article-title":"Moderator's view: Treatment of vascular calcification is a physical impossibility, so far","volume":"30","author":"Wanner","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib0780","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfv020","article-title":"Pro: Cardiovascular calcifications are clinically relevant","volume":"30","author":"Bover","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib0785","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib0790","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1080\/14656566.2016.1182155","article-title":"Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): From treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification","volume":"17","author":"Bover","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.nefro.2016.05.023_bib0795","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/14656566.2016.1182985","article-title":"Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): From treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification","volume":"17","author":"Bover","year":"2016","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.nefro.2016.05.023_bib0800","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2369-12-44","article-title":"Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: A cohort study","volume":"12","author":"Bansal","year":"2011","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.nefro.2016.05.023_bib0805","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1681\/ASN.2012080875","article-title":"High-efficiency posdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients","volume":"24","author":"Maduell","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib0810","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2016.05.023_bib0815","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2016.05.023_bib0820","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.nefro.2016.05.023_bib0825","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.105.568147","article-title":"Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: A multicenter, randomized, double-blind trial","volume":"113","author":"Schmermund","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.nefro.2016.05.023_bib0830","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jacc.2005.02.089","article-title":"Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: The St. Francis Heart Study randomized clinical trial","volume":"46","author":"Arad","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nefro.2016.05.023_bib0835","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2215\/CJN.07460714","article-title":"Statins and cardiovascular primary prevention in CKD: A meta-analysis","volume":"10","author":"Major","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib0840","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4330\/wjc.v6.i5.216","article-title":"Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?","volume":"6","author":"Vo","year":"2014","journal-title":"World J Cardiol."},{"key":"10.1016\/j.nefro.2016.05.023_bib0845","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/ATVBAHA.113.302854","article-title":"Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors","volume":"34","author":"Pruthi","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.nefro.2016.05.023_bib0850","first-page":"53","article-title":"Bone metabolism and cardiovascular function update. Cross link of hypertension, bone loss and vascular calcification \u2014common back grounds in renin angiotensin system with anti-aging aspect\u2014 [Art\u00edculo en japon\u00e9s]","volume":"24","author":"Shimizu","year":"2014","journal-title":"Clin Calcium"},{"key":"10.1016\/j.nefro.2016.05.023_bib0855","doi-asserted-by":"crossref","first-page":"e000949","DOI":"10.1161\/JAHA.114.000949","article-title":"Endoplasmic reticulum stress effector CCAAT\/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification","volume":"3","author":"Miyazaki-Anzai","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nefro.2016.05.023_bib0860","doi-asserted-by":"crossref","first-page":"917","DOI":"10.5551\/jat.23218","article-title":"Pravastatin and olmesartan synergistically ameliorate renal failure-induced vascular calcification","volume":"21","author":"Iijima","year":"2014","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.nefro.2016.05.023_bib0865","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1046\/j.1523-1755.2003.00284.x","article-title":"Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia","volume":"64","author":"Cozzolino","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib0870","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.ki.5002675","article-title":"The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats","volume":"73","author":"Lopez","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib0875","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib0880","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ndt\/gfs356","article-title":"Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study","volume":"28","author":"Urena-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib0885","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ Res."},{"key":"10.1016\/j.nefro.2016.05.023_bib0890","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","article-title":"Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate","volume":"109","author":"Shanahan","year":"2011","journal-title":"Circ Res."},{"key":"10.1016\/j.nefro.2016.05.023_bib0895","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1053\/ajkd.2001.27394","article-title":"Vascular calcification and inorganic phosphate","volume":"38","author":"Giachelli","year":"2001","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2016.05.023_bib0900","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.nefro.2016.05.023_bib0905","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.atherosclerosis.2011.09.002","article-title":"Phosphate: The new cholesterol? The role of the phosphate axis in non-uremic vascular disease","volume":"220","author":"Ellam","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nefro.2016.05.023_bib0910","first-page":"2","article-title":"Papel del f\u00f3sforo en la enfermedad renal cr\u00f3nica","volume":"4","author":"Lloret","year":"2013","journal-title":"Nefrologia suppl."},{"key":"10.1016\/j.nefro.2016.05.023_bib0915","doi-asserted-by":"crossref","first-page":"F1418","DOI":"10.1152\/ajprenal.00633.2013","article-title":"Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia","volume":"306","author":"Yamada","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefro.2016.05.023_bib0920","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/ki.2010.548","article-title":"Phosphate, oxidative stress, and nuclear factor-kappaB activation in vascular calcification","volume":"79","author":"Al-Aly","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib0925","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib0930","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2016.05.023_bib0935","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.nefro.2016.05.023_bib0940","first-page":"207","article-title":"Use of sevelamer in chronic kidney disease: Beyond phosphorus control","volume":"35","author":"Rodriguez-Osorio","year":"2015","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2016.05.023_bib0945","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib0950","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5414\/CNP62104","article-title":"Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification","volume":"62","author":"Braun","year":"2004","journal-title":"Clin Nephrol."},{"key":"10.1016\/j.nefro.2016.05.023_bib0955","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.2215\/CJN.01140211","article-title":"All-cause mortality in hemodialysis patients with heart valve calcification","volume":"6","author":"Raggi","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib0960","first-page":"134","article-title":"Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer","volume":"13","author":"Raggi","year":"2004","journal-title":"J Heart Valve Dis."},{"key":"10.1016\/j.nefro.2016.05.023_bib0965","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1542-4758.2011.00575.x","article-title":"Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: Results from the French ARNOS study","volume":"15","author":"Jean","year":"2011","journal-title":"Hemodial Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib0970","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1093\/ndt\/gfn393","article-title":"Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: Should we CARE-2 avoid them?","volume":"23","author":"Floege","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib0975","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2016.05.023_bib0980","doi-asserted-by":"crossref","first-page":"c273","DOI":"10.1159\/000170783","article-title":"Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nefro.2016.05.023_bib0985","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib0990","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.ajkd.2007.12.002","article-title":"A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data","volume":"51","author":"St Peter","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2016.05.023_bib0995","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/ndt\/gft514","article-title":"Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol","volume":"29","author":"Cozzolino","year":"2014","journal-title":"Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1000","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/ndt\/gfv021a","article-title":"Opponent's comments","volume":"30","author":"Bover","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1005","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1053\/j.ajkd.2014.04.014","article-title":"Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D","volume":"64","author":"Yusuf","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2016.05.023_bib1010","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1517\/14740338.2014.937421","article-title":"Calcium supplementation in chronic kidney disease","volume":"13","author":"Taksande","year":"2014","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.nefro.2016.05.023_bib1015","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","article-title":"Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease","volume":"83","author":"Hill","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ndt\/gfu335","article-title":"Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia","volume":"30","author":"Komaba","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1025","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","article-title":"Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients","volume":"57","author":"Kakuta","year":"2011","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2016.05.023_bib1030","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1440-1797.2010.01412.x","article-title":"Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial","volume":"16","author":"Toussaint","year":"2011","journal-title":"Nephrology (Carlton)."},{"key":"10.1016\/j.nefro.2016.05.023_bib1035","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1542-4758.2009.00364.x","article-title":"Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study","volume":"13","author":"Spiegel","year":"2009","journal-title":"Hemodial Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1040","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s11255-014-0751-9","article-title":"Magnesium retards the progress of the arterial calcifications in hemodialysis patients: A pilot study","volume":"46","author":"Tzanakis","year":"2014","journal-title":"Int Urol Nephrol."},{"key":"10.1016\/j.nefro.2016.05.023_bib1045","first-page":"1147","article-title":"Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: A new oral powder formulation - safety, efficacy, and patient adherence","volume":"7","author":"Lloret","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.nefro.2016.05.023_bib1050","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3109\/0886022X.2014.938544","article-title":"The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: A meta-analysis of randomized trials","volume":"36","author":"Liu","year":"2014","journal-title":"Ren Fail."},{"key":"10.1016\/j.nefro.2016.05.023_bib1055","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","article-title":"Sevelamer versus calcium carbonate in incident hemodialysis patients: Results of an open-label 24-month randomized clinical trial","volume":"62","author":"Di Iorio","year":"2013","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2016.05.023_bib1060","first-page":"CD006023","article-title":"Phosphate binders for preventing and treating bone disease in chronic kidney disease patients","author":"Navaneethan","year":"2011","journal-title":"Cochrane Database Syst. Rev"},{"key":"10.1016\/j.nefro.2016.05.023_bib1065","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/ki.2014.425","article-title":"Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving global outcomes controversies conference","volume":"87","author":"Ketteler","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1070","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/ki.2013.185","article-title":"Use of phosphate-binding agents is associated with a lower risk of mortality","volume":"84","author":"Cannata-Andia","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1075","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.2011.490","article-title":"Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets","volume":"81","author":"Spiegel","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","article-title":"Mortality in kidney disease patients treated with phosphate binders: A randomized study","volume":"7","author":"Di Iorio","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1085","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN107630","article-title":"Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: A pilot study","volume":"80","author":"Lemos","year":"2013","journal-title":"Clin Nephrol."},{"key":"10.1016\/j.nefro.2016.05.023_bib1095","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfv405","article-title":"Pro Should phosphate binders be used in chronic kidney disease stage 3-4?","author":"Bellasi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1100","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfv406","article-title":"Con Phosphate binders in chronic kidney disease","author":"Kestenbaum","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1105","first-page":"196","article-title":"Moderator's view: Phosphate binders in chronic kidney disease patients: A clear No at the moment, but stay tuned","volume":"31","author":"Zoccali","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1110","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1093\/ndt\/gfp350","article-title":"The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: A meta-analysis","volume":"24","author":"Jamal","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2011.69","article-title":"Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis","volume":"80","author":"Russo","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1681\/ASN.2005040342","article-title":"Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol","volume":"17","author":"Lopez","year":"2006","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2016.05.023_bib1125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2008.10.043","article-title":"The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-\/-) mice","volume":"205","author":"Ivanovski","year":"2009","journal-title":"Atherosclerosis"},{"issue":"Suppl 1","key":"10.1016\/j.nefro.2016.05.023_bib1130","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1111\/j.1744-9987.2008.00629.x","article-title":"Change in coronary artery calcification score due to cinacalcet hydrochloride administration","volume":"12","author":"Tsuruta","year":"2008","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nefro.2016.05.023_bib1135","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1140","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2016.05.023_bib1145","doi-asserted-by":"crossref","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","article-title":"Cinacalcet in patients with chronic kidney disease: A cumulative meta-analysis of randomized controlled trials","volume":"10","author":"Palmer","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.nefro.2016.05.023_bib1150","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1210\/jc.2013-2975","article-title":"The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The EVOLVE trial","volume":"98","author":"Parfrey","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.nefro.2016.05.023_bib1155","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1185\/03007990903399398","article-title":"Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy","volume":"25","author":"Wilson","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.nefro.2016.05.023_bib1160","doi-asserted-by":"crossref","first-page":"e16738","DOI":"10.1371\/journal.pone.0016738","article-title":"Renal function is related to severity of coronary artery calcification in elderly persons: The Rotterdam study","volume":"6","author":"El Barzouhi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nefro.2016.05.023_bib1165","article-title":"Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism","author":"Bover","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1170","first-page":"1844","article-title":"Cinacalcet for cardiovascular disease in patients undergoing dialysis","volume":"368","author":"Chertow","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2016.05.023_bib1175","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial","author":"Parfrey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1180","doi-asserted-by":"crossref","first-page":"e001363","DOI":"10.1161\/JAHA.114.001363","article-title":"Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial","volume":"3","author":"Wheeler","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nefro.2016.05.023_bib1185","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2215\/CJN.10221014","article-title":"The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE Trial","volume":"10","author":"Floege","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.nefro.2016.05.023_bib1195","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/ndt\/gfs015","article-title":"Calciphylaxis in CKD and beyond","volume":"27","author":"Brandenburg","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ndt\/gfn502","article-title":"25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients","volume":"24","author":"Matias","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1205","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00198-011-1550-0","article-title":"Low calcidiol levels and risk of progression of aortic calcification","volume":"23","author":"Naves-D\u00edaz","year":"2012","journal-title":"Osteoporos Int."},{"issue":"Suppl 1","key":"10.1016\/j.nefro.2016.05.023_bib1210","first-page":"3","article-title":"Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.)","volume":"31","author":"Torregrosa","year":"2011","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2016.05.023_bib1215","first-page":"28","article-title":"Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease","volume":"35","author":"Bover","year":"2015","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2016.05.023_bib1220","doi-asserted-by":"crossref","first-page":"637065","DOI":"10.1155\/2014\/637065","article-title":"Vascular calcification and renal bone disorders","volume":"2014","author":"Lu","year":"2014","journal-title":"ScientificWorldJournal."},{"key":"10.1016\/j.nefro.2016.05.023_bib1225","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/15701611113119990028","article-title":"Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol)","volume":"12","author":"Bover","year":"2014","journal-title":"Curr Vasc Pharmacol."},{"key":"10.1016\/j.nefro.2016.05.023_bib1230","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.114.010650","article-title":"Vitamin D promotes vascular regeneration","volume":"130","author":"Wong","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.nefro.2016.05.023_bib1235","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/ATVBAHA.113.302525","article-title":"Role of local versus systemic vitamin D receptors in vascular calcification","volume":"34","author":"Lomashvili","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1240","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1681\/ASN.2007080902","article-title":"Vitamin D receptor activators can protect against vascular calcification","volume":"19","author":"Mathew","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1245","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ki.2012.322","article-title":"Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet","volume":"82","author":"Lau","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1250","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.111.053405","article-title":"Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23","volume":"125","author":"Lim","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.nefro.2016.05.023_bib1255","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.ki.5002406","article-title":"Differential effects of vitamin D receptor activators on vascular calcification in uremic rats","volume":"72","author":"Mizobuchi","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1260","doi-asserted-by":"crossref","first-page":"F1136","DOI":"10.1152\/ajprenal.00684.2011","article-title":"In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt\/\u03b2-catenin activation","volume":"303","author":"Mart\u00ednez-Moreno","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1265","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1161\/HYPERTENSIONAHA.114.03748","article-title":"Paricalcitol and endothelial function in chronic kidney disease trial","volume":"64","author":"Zoccali","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.nefro.2016.05.023_bib1270","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2016.05.023_bib1275","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/ndt\/gfn492","article-title":"Mortality reduction by vitamin D receptor activation in end-stage renal disease: A commentary on the robustness of current data","volume":"24","author":"Vervloet","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1280","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/ndt\/gfn592","article-title":"The survival advantage for haemodialysis patients taking vitamin D is questioned: Findings from the Dialysis Outcomes and Practice Patterns Study","volume":"24","author":"Tentori","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1285","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000346846","article-title":"Vitamin D treatment and mortality in chronic kidney disease: A systematic review and meta-analysis","volume":"37","author":"Duranton","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ckj\/sfu122","article-title":"Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: A meta-analysis","volume":"8","author":"Mann","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2016.05.023_bib1295","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/ckj\/sfv104","article-title":"Where is the link between mineral bone markers and cardiovascular disease in CKD?","volume":"8","author":"Cozzolino","year":"2015","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefro.2016.05.023_bib1300","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/clc.20865","article-title":"Association of warfarin use with valvular and vascular calcification: A review","volume":"34","author":"Palaniswamy","year":"2011","journal-title":"Clin Cardiol."},{"key":"10.1016\/j.nefro.2016.05.023_bib1305","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ki.2012.477","article-title":"Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease","volume":"83","author":"McCabe","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1310","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1093\/eurheartj\/ehr226","article-title":"Patients using vitamin K antagonists show increased levels of coronary calcification: An observational study in low-risk atrial fibrillation patients","volume":"32","author":"Weijs","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefro.2016.05.023_bib1315","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2215\/CJN.07450714","article-title":"Vascular calcification in patients with nondialysis CKD over 3 years","volume":"10","author":"Gorriz","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1320","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/ki.2013.26","article-title":"Vitamin K: Key vitamin in controlling vascular calcification in chronic kidney disease","volume":"83","author":"Schurgers","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1325","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ckj\/sfv146","article-title":"The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: Ongoing randomized controlled trials","volume":"9","author":"Caluw\u00e9","year":"2016","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefro.2016.05.023_bib1330","unstructured":"Influence of rivaroxaban compared to vitamin k antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and\/or pulmonary embolism (IRIVASC- Trial). [consultado 7 May 2016]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02066662"},{"key":"10.1016\/j.nefro.2016.05.023_bib1335","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/cer.15.44","article-title":"Atrial fibrillation and chronic kidney disease: Focus on rivaroxaban","volume":"4","author":"Barrios","year":"2015","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.nefro.2016.05.023_bib1340","first-page":"288","article-title":"Use of bisphosphonates in chronic kidney disease","volume":"30","author":"Torregrosa","year":"2010","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2016.05.023_bib1345","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2008.646","article-title":"Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure","volume":"75","author":"Lomashvili","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1350","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0272-6386(04)00937-0","article-title":"Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis","volume":"44","author":"Nitta","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2016.05.023_bib1355","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1744-9987.2006.00345.x","article-title":"Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: Long-term effects","volume":"10","author":"Hashiba","year":"2006","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nefro.2016.05.023_bib1360","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00198-004-1662-x","article-title":"Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women","volume":"16","author":"Tank\u00f3","year":"2005","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1365","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","article-title":"Effect of alendronate on vascular calcification in CKD stages 3 and 4: A pilot. randomized controlled trial","volume":"56","author":"Toussaint","year":"2010","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2016.05.023_bib1370","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1161\/CIRCULATIONAHA.113.001534","article-title":"Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: A randomized, controlled trial","volume":"127","author":"Kawahara","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.nefro.2016.05.023_bib1375","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.semnephrol.2014.09.008","article-title":"Adynamic bone disease: From bone to vessels in chronic kidney disease","volume":"34","author":"Bover","year":"2014","journal-title":"Semin Nephrol."},{"key":"10.1016\/j.nefro.2016.05.023_bib1380","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1681\/ASN.2007050622","article-title":"Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD","volume":"19","author":"London","year":"2008","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2016.05.023_bib1385","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/BOR.0000000000000169","article-title":"Current approaches to osteoporosis treatment","volume":"27","author":"Lim","year":"2015","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.nefro.2016.05.023_bib1390","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2215\/CJN.09880912","article-title":"Sodium thiosulfate therapy for calcific uremic arteriolopathy","volume":"8","author":"Nigwekar","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1395","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/ndt\/gfp755","article-title":"Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients","volume":"25","author":"Adirekkiat","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1400","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000323550","article-title":"Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: A pilot study of feasibility, safety and efficacy","volume":"33","author":"Mathews","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1405","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00223-013-9780-0","article-title":"Efficacy of reversal of aortic calcification by chelating agents","volume":"93","author":"Lei","year":"2013","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.nefro.2016.05.023_bib1410","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/ndt\/gfr375","article-title":"The chemistry of thiosulfate and vascular calcification","volume":"27","author":"O\u2019Neill","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1415","doi-asserted-by":"crossref","unstructured":"Perell\u00f3 J, Salcedo C, Joubert PH, Canals A, Ferrer M. First-time-in-human phase 1 clinical trial in healthy volunteers with SNF472, a novel inhibitor of vascular calcification. Nephrol Dial Transplant. 2015;30 (suppl 3):ii592. (abstract).","DOI":"10.1093\/ndt\/gfv199.13"},{"key":"10.1016\/j.nefro.2016.05.023_bib1420","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2741\/1786","article-title":"Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats","volume":"11","author":"Grases","year":"2006","journal-title":"Front Biosci."},{"key":"10.1016\/j.nefro.2016.05.023_bib1425","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1253\/circj.71.1152","article-title":"Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: A pilot study in Sprague-Dawley rats","volume":"71","author":"Grases","year":"2007","journal-title":"Circ J."},{"issue":"suppl 3","key":"10.1016\/j.nefro.2016.05.023_bib1430","doi-asserted-by":"crossref","first-page":"Iii588","DOI":"10.1093\/ndt\/gfv199.02","article-title":"MDF. SNF472 inhibits the progression of vitamin D induced cardiovascular calcification in rats","volume":"30","author":"Perell\u00f3","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1435","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1111\/j.1600-6143.2009.02814.x","article-title":"Evolution of coronary artery calcifications following kidney transplantation: Relationship with osteoprotegerin levels","volume":"9","author":"Bargnoux","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1440","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.ajkd.2011.07.019","article-title":"Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients","volume":"59","author":"Mar\u00e9chal","year":"2012","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2016.05.023_bib1445","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1093\/ndt\/gfr558","article-title":"Progression of coronary artery calcification in renal transplant recipients","volume":"27","author":"Seyahi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1450","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2215\/CJN.03930808","article-title":"Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation","volume":"4","author":"Mazzaferro","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1455","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1258\/0969141053279086","article-title":"Current concepts in screening for noncommunicable disease: World Health Organization Consultation Group Report on methodology of noncommunicable disease screening","volume":"12","author":"Strong","year":"2005","journal-title":"J Med Screen"},{"key":"10.1016\/j.nefro.2016.05.023_bib1460","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMp038136","article-title":"Novel risk markers and clinical practice","volume":"349","author":"Manolio","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2016.05.023_bib1465","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2215\/CJN.04290510","article-title":"Large artery calcification on dialysis patients is located in the intima and related to atherosclerosis","volume":"6","author":"Coll","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1470","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000325656","article-title":"Coronary artery calcification progression is associated with arterial stiffness and cardiac repolarization deterioration in hemodialysis patients","volume":"34","author":"Di Iorio","year":"2011","journal-title":"Kidney Blood Press Res."},{"key":"10.1016\/j.nefro.2016.05.023_bib1475","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1148\/radiol.2241011191","article-title":"Calcium begets calcium: Progression of coronary artery calcification in asymptomatic subjects","volume":"224","author":"Yoon","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.nefro.2016.05.023_bib1480","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/ndt\/gfs108","article-title":"VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH \u2264 150pg\/mL: Results of the Italian FARO Survey","volume":"27","author":"Cozzolino","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.05.023_bib1485","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.nefro.2015.06.015","article-title":"Haemodialysis session: The perfect storm for vascular calcification","volume":"35","author":"Seras","year":"2015","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2016.05.023_bib1490","doi-asserted-by":"crossref","DOI":"10.1016\/j.nefro.2016.01.002","article-title":"Comment to: Haemodialysis session: The perfect storm for vascular calcification","author":"Villa-Bellosta","year":"2016","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2016.05.023_bib1495","article-title":"Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis","author":"Ok","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.05.023_bib1500","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000337832","article-title":"Role of vitamin D receptor activators in peritoneal dialysis","volume":"178","author":"Bover","year":"2012","journal-title":"Contrib Nephrol."}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021169951630090X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021169951630090X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T02:21:31Z","timestamp":1568341291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021169951630090X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":150,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S021169951630090X"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2016.05.023","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}